Elevated plasma chromogranin-A concentrations in prostatic carcinoma.
Chromogranin-A is considered a sensitive immunohistochemical tissue marker in neuroendocrine prostatic carcinoma. We report that the plasma chromogranin-A level was elevated in 48% of 25 patients with stage D2 prostate cancer, and suggest that this marker can be used to monitor the clinical course of these patients.
Kadmon
D
D
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030.
Thompson
T C
TC
Lynch
G R
GR
Scardino
P T
PT
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002277:Carcinoma / Q000097:blood*; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood*; D011863:Radioimmunoassay
D015415:Biomarkers; C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins